tirzepatide cancelled for Weight Loss FDA Announces End To Compounded
Description
PMID 39844933
Adults with obesity or weight-related health conditions may qualify, depending on medical history and clinical assessment
Cost: Pricing and insurance coverage are unclear since it hasnt yet been released
diarrhoea)
However, no human clinical trials have been completed yet, and tirzepatide has no FDA approval for substance use disorders
Semaglutide for the treatment of overweight and obesity: A review
